key: cord-0940062-vfdtbolx
authors: Lim, Xin Rong; Leung, Bernard PuiLam; Sum, Christina Lai Lin; Lim, Gek Hsiang; Chua, Choon Guan; Tu, Tian Ming; Ramanathan, Kollengode; Huang, Mei Yan; Howe, Hwee Siew; Fan, Bingwen Eugene
title: BNT162b2 mRNA SARS‐CoV‐2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single‐arm, longitudinal study
date: 2022-01-19
journal: Am J Hematol
DOI: 10.1002/ajh.26462
sha: bf95302bee0cdea09c607e9b4d947b1f66fe6b3c
doc_id: 940062
cord_uid: vfdtbolx

nan

T A B L E 1 Descriptive statistics of endothelial activation markers and coagulation parameters pre and post BNT162b2 vaccine 

Safety Updates on COVID-19. Health Sciences Authority

Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: a black swan event

No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2

Absence of hypercoagulability after nCoV-19 vaccination: an observational pilot study

COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study